BioSpace News Archive

Cannabics Pharmaceuticals Inc. announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has completed clinical site selection for its ABV-1505 Attention-Deficit Hyperactivity Disorder (ADHD) Phase II Part 2 study.

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and their functions in the body can effectively be used in clinical care.

Taiho Oncology, Inc. which specializes in orally administered anti-cancer medicines and whose mission is to improve the lives of patients with cancer, their families and their caregivers, announced data presentations from several studies for two of its investigational agents at the European Society for Medical Oncology Congress 2021.

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics).

Y2X Life Sciences, a New York-based leader in products that disrupt the transmission of infectious disease, today announced it has entered into an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology that can detect aerosolized SARS-CoV-2.

TG Therapeutics, Inc., today recapped the schedule of upcoming data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 – 20, 2021.

Paul Brennan, NervGen’s President and CEO, will provide an overview of the Company’s operations and the development plans for its lead compound, NVG-291.

Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant (each a “Warrant”).

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.